Browse the evidence

Mendelian randomisation did not find evidence that genetically proxied GLP-1RA increased suicide attempts in a general population cohort.

There is no genetic evidence to support an association between GLP-1RA and increased suicide attempts, suggesting safety in this regard.

There is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.

Clinicians should be cautious and consider FDA approval status when prescribing incretin analogs.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Approximately 10% of obesity-related glomerulopathy (ORG) patients progress to end stage renal disease 6.2 years after diagnosis.

Healthcare providers should monitor ORG patients closely for progression to end stage renal disease.

The pathogenesis of obesity-related glomerulopathy is complex, involving multiple factors.

Recognizing the complexity of ORG can guide more targeted therapeutic approaches.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Amylin and salmon calcitonin target distinct neurons in various brain regions.

Insights into neural targeting can inform obesity treatment strategies.

The internet-based marketing of plant-based formulations for enhancing metabolism has surged.

Practitioners should be aware of the growing trend in plant-based metabolism enhancers in the market.

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

The use of GLP-1RA medications has been associated with increased hypoglycaemia risk in patients treated with concomitant antihyperglycaemic medications.

Clinicians should monitor for hypoglycaemia when initiating GLP-1RA therapy in patients on other antihyperglycaemic medications.

GIP(1-30)NH2 and GIP(1-42) have similar effects on human pancreatic islets.

Both GIP variants can be expected to have similar effects on insulin and glucagon secretion in pancreatic islets.

There were no significant between-group differences in VAT volume after 6 months or 12 months.

Dietary interventions may not differ significantly in their effects on VAT volume over time.

Statins have not mitigated the incidence or prevalence of cardiovascular disease (CVD).

Practitioners should reconsider the reliance on statins for CVD prevention.

The SDOC definition has high discriminatory accuracy for identifying ADL disability.

The SDOC criteria can be effectively used to assess risk of ADL disability in older adults.

Demographics associated with higher prescription period prevalence included non-Hispanic Black race and ethnicity, female sex, and older age.

Understanding these demographic factors can help tailor interventions and support for specific groups.

Semaglutide is available in two formulations: once-weekly subcutaneous and once-daily oral.

Practitioners can offer patients a choice between two formulations of semaglutide for weight management.

Further study is needed to understand GIP's implications on weight reduction and other diseases.

Practitioners should be aware of the potential broader implications of GIP therapies.

Only 8% of eligible candidates with type 2 diabetes are prescribed GLP-1RA.

Cardiologists should be aware of the low prescription rates of GLP-1RA among eligible patients.

The uptake of GLP-1RA in clinical practice is low among cardiologists.

Efforts are needed to increase awareness and education among cardiologists regarding GLP-1RA.

The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.

This formulation may provide a long-lasting treatment option for diabetes management.

The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.

Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.

If 1%, 5%, or 10% of the population aged 60 years or older is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.

Understanding these cost projections is crucial for policymakers and healthcare planners.